AMELIA AUBUCHON: Open Payments
NPI 1881246908 · SAINT PETERS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$695 in 26 payments from 11 companies in 2025. Trend: 2023 $876 · 2024 $3,170 · 2025 $695
Food & beverage: $695
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 6 | $200 |
| Regeneron Healthcare Solutions, Inc. | 2 | $154 |
| ABBVIE INC. | 5 | $89 |
| Janssen Biotech, Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $35 |
| GENZYME CORPORATION | 1 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| PFIZER INC. | 1 | $17 |
Products named: DUPIXENT, ZENPEP, TREMFYA, RINVOQ, VOWST, ENTYVIO, OMVOH, CREON.
Industry payments across MO — which companies pay providers there.
